1. At a Glance
Marksans Pharma just reported Q3 FY26 revenue of ₹754.4 crore (+10.6% YoY) and PAT of ₹113.7 crore (+8.3% YoY), and yes, this is one of those rare Indian pharma companies where OTC actually means serious money, not just cough syrup nostalgia. With a market cap of ~₹7,900 crore, ROCE ~20%, debt-to-equity of 0.12, and 21% operating margins, Marksans looks like that quiet topper who never raises his hand but still scores 90+.
But the stock is down ~33% over one year, FIIs have done a disappearing act in recent quarters, and working capital days are stretching like a yoga instructor in Goa. So what’s going on here? Is the market bored of stable OTC cash flows? Or is this just a classic case of “good business, bad timing”?
This quarter matters because it confirms three things:
- OTC-led growth is intact, especially in the US and UK.
- Margins are holding, despite cost pressures and expansion.
- CAPEX is peaking, which means free cash flow questions will get louder.
Let’s dissect this calmly, sarcastically, and with a calculator in hand.
2. Introduction – The Most Unsexy Pharma Story That Actually Works
Marksans Pharma is not a discovery-led biotech. It’s not chasing blockbuster oncology molecules or shouting about GLP-1 obesity drugs. Instead, it sells ibuprofen, paracetamol, cough syrups, vitamins, gels, and liquids—basically the stuff you buy when your throat hurts, your head hurts, or life hurts.
And yet, this “boring” portfolio has quietly built a global OTC and private-label empire across the US, UK, Europe, Australia, and emerging markets.
What makes Marksans interesting is not innovation hype but execution discipline:
- 300+ approved products
- 1,500+ SKUs
- Presence in some of the most regulated markets globally
- Long-standing relationships with retailers like Walmart, Target, Tesco, Boots, Woolworths
In a sector where many Indian pharma companies still rely on price hikes
